WallStreetZenWallStreetZen

NASDAQ: PACB
Pacific Biosciences Of California Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PACB

Based on 6 analysts offering 12 month price targets for Pacific Biosciences Of California Inc

Min Forecast
$1.50+35.14%
Avg Forecast
$2.17+95.23%
Max Forecast
$3.00+170.27%

Should I buy or sell PACB stock?

Based on 6 analysts offering ratings for Pacific Biosciences Of California Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
1 analysts 16.67%
Hold
3 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PACB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PACB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PACB stock forecasts and price targets.

PACB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-03-25
lockedlocked$00.00+00.00%2025-02-20
lockedlocked$00.00+00.00%2025-02-18
lockedlocked$00.00+00.00%2025-02-18
UBS
Bottom 3%
3
HoldDowngrades$2.00+80.18%2024-11-11

1 of 1

Forecast return on equity

Is PACB forecast to generate an efficient return?

Company
-27.05%
Industry
23.04%
Market
61.57%
PACB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PACB forecast to generate an efficient return on assets?

Company
-10.87%
Industry
12.31%
PACB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PACB earnings per share forecast

What is PACB's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.71
Avg 2 year Forecast
-$0.61
Avg 3 year Forecast
-$0.46

PACB revenue forecast

What is PACB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$158.7M+3.07%
Avg 2 year Forecast
$203.8M+32.31%
Avg 3 year Forecast
$265.7M+72.49%
PACB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PACB revenue growth forecast

How is PACB forecast to perform vs Medical Devices companies and vs the US market?

Company
16.39%
Industry
8.56%
Market
10.43%
PACB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PACB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PACB vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
PACB$1.11$2.17+95.23%Buy
TCMD$14.12$18.00+27.48%Hold
NNOX$5.03$12.00+138.57%Strong Buy
VREX$8.32$22.50+170.43%Strong Buy
SMLR$32.33$71.00+119.61%Strong Buy
View Top Medical Device Stocks

Pacific Biosciences Of California Stock Forecast FAQ

Is Pacific Biosciences Of California Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PACB) stock is to Buy PACB stock.

Out of 6 analysts, 2 (33.33%) are recommending PACB as a Strong Buy, 1 (16.67%) are recommending PACB as a Buy, 3 (50%) are recommending PACB as a Hold, 0 (0%) are recommending PACB as a Sell, and 0 (0%) are recommending PACB as a Strong Sell.

If you're new to stock investing, here's how to buy Pacific Biosciences Of California stock.

What is PACB's earnings growth forecast for 2025-2027?

(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 23.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.32%.

Pacific Biosciences Of California's earnings in 2025 is -$309,851,000.On average, 5 Wall Street analysts forecast PACB's earnings for 2025 to be -$211,475,082, with the lowest PACB earnings forecast at -$217,432,126, and the highest PACB earnings forecast at -$205,518,037. On average, 5 Wall Street analysts forecast PACB's earnings for 2026 to be -$181,689,859, with the lowest PACB earnings forecast at -$202,539,515, and the highest PACB earnings forecast at -$134,033,503.

In 2027, PACB is forecast to generate -$137,012,025 in earnings, with the lowest earnings forecast at -$169,775,770 and the highest earnings forecast at -$92,334,191.

What is PACB's revenue growth forecast for 2025-2027?

(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 16.39% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.56%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.43%.

Pacific Biosciences Of California's revenue in 2025 is $154,014,000.On average, 4 Wall Street analysts forecast PACB's revenue for 2025 to be $47,280,169,116, with the lowest PACB revenue forecast at $46,167,095,340, and the highest PACB revenue forecast at $48,803,087,558. On average, 5 Wall Street analysts forecast PACB's revenue for 2026 to be $60,696,029,170, with the lowest PACB revenue forecast at $56,294,071,092, and the highest PACB revenue forecast at $66,802,297,696.

In 2027, PACB is forecast to generate $79,127,125,038 in revenue, with the lowest revenue forecast at $70,531,407,590 and the highest revenue forecast at $87,100,927,034.

What is PACB's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: PACB) forecast ROA is -10.87%, which is lower than the forecast US Medical Devices industry average of 12.31%.

What is PACB's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PACB price target, the average PACB price target is $2.17, with the highest PACB stock price forecast at $3.00 and the lowest PACB stock price forecast at $1.50.

On average, Wall Street analysts predict that Pacific Biosciences Of California's share price could reach $2.17 by Apr 10, 2026. The average Pacific Biosciences Of California stock price prediction forecasts a potential upside of 95.23% from the current PACB share price of $1.11.

What is PACB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PACB) Pacific Biosciences Of California's current Earnings Per Share (EPS) is -$1.13. On average, analysts forecast that PACB's EPS will be -$0.71 for 2025, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at -$0.69. On average, analysts forecast that PACB's EPS will be -$0.61 for 2026, with the lowest EPS forecast at -$0.68, and the highest EPS forecast at -$0.45. In 2027, PACB's EPS is forecast to hit -$0.46 (min: -$0.57, max: -$0.31).

What is PACB's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: PACB) forecast ROE is -27.05%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.